Oncotelic Therapeutics, Inc.
Ticker: 908259
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q2 FY26 | Q3 FY23 | Q3 FY23 | Q2 FY20 |
|---|---|---|---|---|
| INCOME | ||||
| Revenue | 0.25+257.1% | 0.07+0.0% | 0.07-95.0% | 1.40 |
| Total Income | 0.25+257.1% | 0.07+0.0% | 0.07-95.0% | 1.40 |
| EXPENSES | ||||
| Expenditure | 1.09+1716.7% | 0.06+0.0% | 0.06-95.7% | 1.39 |
| PROFIT | ||||
| Net Profit | 0.39+225.0% | 0.12+0.0% | 0.12-79.3% | 0.58 |
| KEY METRICS | ||||
| OPM % | -100.00%-120.68pp | 20.68% | 20.68%+19.69pp | 0.99% |
| NPM % | 100.00% | 100.00% | 100.00%+58.42pp | 41.58% |
| EPS | 0.00 | 0.00 | 0.00-100.0% | 0.01 |
Corporate Events
Board MeetingOTLC
202610Jul
Board Meeting
Board approved granting of Restricted Stock Units (RSUs) to …
SEC Filing ↗